| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Izalontamab | SI-B001; SI-1X6.4 | Phase 3 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Neoplasms, Glandular and Epithelial; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | 詳細 |
| JSKN-016 | JSKN-016; JSKN016 | Phase 3 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | 詳細 |
| YL-202 | YL-202; BNT326 | Phase 3 Clinical | MediLink Therapeutics Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms | 詳細 |
| SHR-A2009 | SHR-A2009 | Phase 3 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Solid tumours; Triple Negative Breast Neoplasms | 詳細 |
| Patritumab Deruxtecan | U3-1402; U3-1402a; MK-1022 | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Brain metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Melanoma; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 詳細 |
| Nezutatug | HMBD-001 | Phase 2 Clinical | Hummingbird Bioscience | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 詳細 |
| Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Plc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 詳細 |
| HMBD-501 | ENV-501; HMBD-501; ENV-ONC-501 | Phase 2 Clinical | Hummingbird Bioscience | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Skin Melanoma | 詳細 |
| JS-212 | JS212; JS-212 | Phase 2 Clinical | Shanghai Junshi Biosciences Co Ltd | Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Solid tumours | 詳細 |
| DB-1418 | AVZO-1418; DB-1418 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Lung Neoplasms; Neoplasms, Glandular and Epithelial; Solid tumours | 詳細 |
| 89Zr-Patritumab deruxtecan | Phase 2 Clinical | Daiichi Sankyo Co Ltd, Daiichi Sankyo Inc, The Netherlands Cancer Institute | Carcinoma, Non-Small-Cell Lung | 詳細 | |
| IBI-133 | IBI133; IBI-133 | Phase 2 Clinical | Solid tumours | 詳細 | |
| DB-1310 | DB-1310 | Phase 2 Clinical | Duality Biologics (Shanghai) Co Ltd, Duality Biologics (Suzhou) Co Ltd | Neoplasm Metastasis; Solid tumours | 詳細 |
| SIBP-03 | SIBP-03 | Phase 2 Clinical | Shanghai Institute of Biological Products Co Ltd | Neoplasms; Squamous Cell Carcinoma of Head and Neck | 詳細 |
| JK-07 (SalubrisBio) | JK07; SAL007; SAL-007 | Phase 2 Clinical | Salubris Biotherapeutics Inc | Heart Failure; Heart Failure, Diastolic; Heart Failure, Systolic; Pulmonary Arterial Hypertension | 詳細 |
| Recombinat humanized HER3-targeting antibody | Phase 2 Clinical | Shanghai Institute of Biological Products Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck | 詳細 | |
| Elgemtumab | NOV-6; LJM-716 | Phase 1 Clinical | Morphosys Ag, Novartis Pharma Ag | Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | 詳細 |
| MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Phase 1 Clinical | Molecular Partners Ag | Neoplasms | 詳細 |
| AV-203 | AV-203; CAN-017 | Phase 1 Clinical | Aveo | Neoplasms; Solid tumours | 詳細 |
| HDM-2024 | HDM2024; HDM-2024 | Phase 1 Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd | Solid tumours | 詳細 |
| KHN-922 | KHN-922 | Phase 1 Clinical | Chengdu Kanghong Pharmaceutical Group Co Ltd | Neoplasms; Solid tumours | 詳細 |
| Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Stomach Neoplasms | 詳細 |
| PM1300 | PM-1300; PM1300 | Phase 1 Clinical | Neoplasms | 詳細 | |
| AK-138-D-1 | AK138D1; AK-138-D-1 | Phase 1 Clinical | Neoplasms; Solid tumours | 詳細 | |
| BL-B16D1 | BLB16D1; BL-B16D1 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | 詳細 |
| SYS-6023 | SYS-6023; SYS6023 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Breast Neoplasms; Metastatic breast cancer; Solid tumours | 詳細 |
| AMT-562 | AMT-562 | Phase 1 Clinical | Multitude Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| SIBP-A13 | SIBP-A13 | Phase 1 Clinical | Shanghai Institute of Biological Products Co Ltd | Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Metastatic breast cancer; Solid tumours | 詳細 |
| Recombinant human ErbB3 fragment vaccine (Zensun) | rhErbB3-f | Phase 1 Clinical | Zensun (Shanghai) Sci&Tech Co Ltd | Neoplasms | 詳細 |
| DM-002 | DM-002; DM002 (Danma) | Phase 1 Clinical | Danma (Suzhou) Biomedical Technology Co Ltd | Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Solid tumours | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Plc | 泰瑞沙, Tagrisso | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2015-11-13 | Adenocarcinoma; Adenocarcinoma of Lung; Brain metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Meningeal Neoplasms; Multiple Myeloma; Neoplasm, Residual; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | 詳細 |
| Zenocutuzumab | MCLA-128 | Approved | Merus Nv | Bizengri | United States | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Merus Nv | 2024-12-04 | Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours | 詳細 |